Behçet Disease Clinical Trials and Treatments

Behçet Disease is a chronic, recurrent systemic vasculitis affecting small, medium, and large vessels of multiple organ systems. The pathophysiology involves abnormal T cell activation, increased Th1/Th17 responses, and immune complex deposition leading to vessel inflammation. The disease is characterized by recurrent oral and genital ulceration, which occurs in nearly all patients.

The most common symptoms of Behçet Disease include Recurrent painful oral ulcers (aphthous stomatitis), Recurrent genital ulcers, Ocular involvement with eye pain, redness, and vision loss (uveitis), Skin lesions including erythema nodosum and pseudofolliculitis, Vascular complications including thrombosis, among others. Estimated 3-300 cases per 100,000 depending on geography; highest in Turkey (370 per 100,000), common in Middle East and East Asia, rare in North America and Northern Europe. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Behçet Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Behçet Disease is advancing through biologic therapies targeting specific immune mechanisms driving the disease. TNF inhibitors like infliximab, etanercept, and adalimumab have demonstrated real efficacy in reducing disease activity, particularly for the serious ocular and neurologic complications that threaten vision and neurologic function.

Yes. As of September 2026, Trial Friend lists 2 FDA-approved drugs used to treat Behçet Disease: Humira (adalimumab), first approved in 2002; and Otezla (apremilast), first approved in 2019.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

The exact cause of Behçet Disease is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. HLA-B*51 raises risk but is not diagnostic; no gene test exists. Estimated 3-300 cases per 100,000 depending on geography; highest in Turkey (370 per 100,000), common in Middle East and East Asia, rare in North America and Northern Europe. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Behçet Disease. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. HLA-B*51 raises risk but is not diagnostic; no gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Behçet Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Behçet Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.